Affiliation:
1. Cancer Center, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai 519000, China
2. Department of Gynecologic Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou 510060, China
Abstract
Epithelial ovarian cancer is by far the most lethal gynecological malignancy. The exploration of promising immunomarkers to predict prognosis in ovarian cancer patients remains challenging. In our research, we carried out an integrated bioinformatic analysis of genome expressions and their immune characteristics in the ovarian cancer microenvironment with validation in different experiments. We filtrated 332 differentially expressed genes with 10 upregulated hub genes from the Gene Expression Omnibus database. These genes were closely related to ovarian tumorigenesis. Subsequently, the survival and immune infiltration analysis demonstrated that the upregulation of five candidate genes, ITGB2, VEGFA, CLDN4, OCLN, and SPP1, were correlated with an unfavorable clinical outcome and increased immune cell infiltration in ovarian cancer. Of these genes, ITGB2 tended to be the gene most correlated with various immune cell infiltrations and had a strong correlation with significant M2 macrophages infiltration (r = 0.707, p = 4.71 × 10−39), while it had a moderate correlation with CD4+/CD8+ T cells and B cells. This characteristic explains why the high expression of ITGB2 was accompanied by immune activation but did not reverse carcinogenesis. Additionally, we confirmed that ITGB2 was over-expressed in ovarian cancer tissues and was mainly located in cytoplasm, detected by Western blotting and the immunohistochemical method. In summary, ITGB2 may serve as a prognostic immunomarker for ovarian cancer patients.
Funder
National Natural Science Foundation of China
Reference37 articles.
1. Diagnosis and Treatment of Ovarian Cancer;Orr;Hematol. Oncol. Clin. N. Am.,2018
2. Senescence induction dictates response to chemo- and immunotherapy in preclinical models of ovarian cancer;Paffenholz;Proc. Natl. Acad. Sci. USA,2022
3. Development of Immunotherapy Combination Strategies in Cancer;Yap;Cancer Discov.,2021
4. Immunotherapy: Cancer immunotherapy and the value of cure;Nat. Rev. Clin. Oncol.,2018
5. Exploration of the underlying biological differences and targets in ovarian cancer patients with diverse immunotherapy response;Chen;Front. Immunol.,2022